Robert McRae
Plus aucun poste en cours
Fortune : 1 735 $ au 31/03/2024
Profil
Robert McRae worked as Vice President-Operations at Viracta Subsidiary, Inc. from 2018 to 2020.
He also held the position of Vice President-Operations & Strategic Alliances at Viracta Therapeutics, Inc. Additionally, he served as Chief Operating Officer at Palisade Bio, Inc. in 2023.
Mr. McRae obtained his undergraduate degree from Wright State University (Ohio).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PALISADE BIO, INC.
0,03% | 15/03/2024 | 4 348 ( 0,03% ) | 1 735 $ | 31/03/2024 |
Anciens postes connus de Robert McRae
| Sociétés | Poste | Fin |
|---|---|---|
| PALISADE BIO, INC. | Chief Operating Officer | 01/05/2023 |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Chief Operating Officer | - |
Formation de Robert McRae
| Wright State University (Ohio) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| PALISADE BIO, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
